Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $8,188 | 1 | 61.7% |
| Consulting Fee | $4,886 | 10 | 36.8% |
| Food and Beverage | $191.12 | 3 | 1.4% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca UK Limited | $13,074 | 11 | $0 (2023) |
| ABBVIE INC. | $171.62 | 2 | $0 (2022) |
| Genentech, Inc. | $19.50 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $3,170 | 5 | AstraZeneca UK Limited ($3,170) |
| 2022 | $1,176 | 5 | AstraZeneca UK Limited ($1,004) |
| 2021 | $712.50 | 2 | AstraZeneca UK Limited ($712.50) |
| 2017 | $8,207 | 2 | AstraZeneca UK Limited ($8,188) |
All Payment Transactions
14 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/21/2023 | AstraZeneca UK Limited | BREZTRI (Drug) | Consulting Fee | Cash or cash equivalent | $719.50 | General |
| Category: Respiratory | ||||||
| 09/21/2023 | AstraZeneca UK Limited | BREZTRI (Drug) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: Respiratory | ||||||
| 06/16/2023 | AstraZeneca UK Limited | BREZTRI (Drug) | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| Category: Respiratory | ||||||
| 04/20/2023 | AstraZeneca UK Limited | BREZTRI (Drug) | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| Category: Respiratory | ||||||
| 04/20/2023 | AstraZeneca UK Limited | BREZTRI (Drug) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: Respiratory | ||||||
| 10/13/2022 | AstraZeneca UK Limited | BREZTRI (Drug) | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| Category: Respiratory | ||||||
| 10/13/2022 | AstraZeneca UK Limited | BREZTRI (Drug) | Consulting Fee | Cash or cash equivalent | $175.00 | General |
| Category: Respiratory | ||||||
| 07/27/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $62.16 | General |
| Category: NEUROSCIENCE | ||||||
| 04/20/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $109.46 | General |
| Category: NEUROSCIENCE | ||||||
| 02/03/2022 | AstraZeneca UK Limited | BREZTRI (Drug) | Consulting Fee | Cash or cash equivalent | $129.00 | General |
| Category: Respiratory | ||||||
| 07/15/2021 | AstraZeneca UK Limited | BREZTRI (Drug) | Consulting Fee | Cash or cash equivalent | $356.25 | General |
| Category: Respiratory | ||||||
| 07/15/2021 | AstraZeneca UK Limited | BREZTRI (Drug) | Consulting Fee | Cash or cash equivalent | $356.25 | General |
| Category: Respiratory | ||||||
| 05/23/2017 | Genentech, Inc. | Xolair (Biological) | Food and Beverage | In-kind items and services | $19.50 | General |
| Category: Immunology | ||||||
| 02/17/2017 | AstraZeneca UK Limited | — | — | Cash or cash equivalent | $8,187.50 | Research |
| Study: High dose ICS LABA 2ndController Study SIROCCO | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| High dose ICS LABA 2ndController Study SIROCCO | AstraZeneca UK Limited | $8,188 | 1 |
About Thomas Murphy
Thomas Murphy is a Pulmonary Disease healthcare provider based in Durham, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/09/2007. The National Provider Identifier (NPI) number assigned to this provider is 1295884211.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Thomas Murphy has received a total of $13,265 in payments from pharmaceutical and medical device companies, with $3,170 received in 2023. These payments were reported across 14 transactions from 3 companies. The most common payment nature is "" ($8,188).
Practice Information
- Specialty Pulmonary Disease
- Other Specialties Pediatrics
- Location Durham, NC
- Active Since 01/09/2007
- Last Updated 06/05/2012
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1295884211
Products in Payments
- BREZTRI (Drug) $4,886
- VRAYLAR (Drug) $171.62
- Xolair (Biological) $19.50
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Durham
Laurie Snyder, Md, MD
Pulmonary Disease — Payments: $140,144
Scott Palmer, M.d, M.D
Pulmonary Disease — Payments: $125,081
Eric Meltzer, Md, MD
Pulmonary Disease — Payments: $42,908
Donald Rabil, Md, MD
Pulmonary Disease — Payments: $17,077
Dr. Scott Shofer, M.d., Ph.d, M.D., PH.D
Pulmonary Disease — Payments: $8,376
Loretta Que, Md, MD
Pulmonary Disease — Payments: $4,017